期刊文献+

利莫那班衍生物对高脂肥胖模型小鼠的减肥作用 被引量:3

Lose-weight effect on high fat diet-induced obese mice of analogues of rimonabant ZH-101-S
下载PDF
导出
摘要 目的:观察利莫那班衍生物ZH-101-S对高脂饲料饲喂小鼠的减肥作用。方法:以高脂饲料喂养ICR雄性小鼠1月建立高脂肥胖模型。将小鼠随机分为5组,对照组、高脂模型组、利莫那班30 mg/kg组、ZH-101-S 10 mg/kg组和ZH-101-S 30 mg/kg组。正常组和模型组给予0.5%的羧甲基纤维素钠,其他3组分别给予相应的药物,各组均连续灌胃给药18 d。实验过程中测量小鼠体质量,末次给药后空腹12 h,眼眶采血检测小鼠空腹血清总胆固醇、三酰甘油、高密度脂蛋白胆固醇(HDL-C)、血糖、极低密度脂蛋白胆固醇(LDL-C)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、乳酸脱氢酶(LDH)水平。处死小鼠,取附睾脂肪称重并计算脂肪系数(附睾脂肪质量/净体重),并将脂肪及肝脏组织进行切片和HE染色。结果:连续给药18 d后ZH-101-S组小鼠体质量、血清总胆固醇、三酰甘油、血糖、LDL-C、AST、ALT、LDH水平均明显低于模型组(P<0.05),HDL-C较模型组明显升高;光镜下,ZH-101-S组脂肪细胞直径、肝组织脂滴空泡数均明显小于或少于模型组。结论:利莫那班衍生物ZH-101-S在减轻高脂肥胖模型小鼠体质量的同时能降低血脂水平,改善肝损伤。 Objective: To investigate the mechanism of analogues of rimonabant ZH-101-S lose-weight effect on high-fat diet-induced obese mice. Methods: Male ICR mice were fed with high fat diet to build the obese mice model and the mice were divided into control group, obese model group, rimonabant group (30 mg/kg)and ZH-101-S group (15 mg/kg, 30 mg/kg). All drug were administered by intragastric ad- ministration per day for 18 days. Body weight and the content/morphology of genital peripheral adipose tis- sue and morphology of liver were detected, the content of total cholesterol, triacylglycerol, high density lipo- protein cholesterol ( HDL-C ), glucose, low density lipoprotein cholesterol ( LDL-C ), glutamic-oxalacetic transaminase ( AST), glutamic-pyruvic transaminase (ALT) and lactic dehydrogenase (LDH) in serum were also estimated. Results: After treated with ZH-101-S for 18 days, the bodyweight of mice and the content of genital peripheral adipose tissue were significantly reduced, compared with model group. ZH-101-S could decrease the level of triacylglycerol,total cholesterol,LDL-C, LDH in serum and elevate the level of HDL- C. Finally, ZH-101-S protected high fat food induced hepatic injury proved by AST and ALT decrease and improvement of liver morphology. Conclusion: ZH-101-S could reduce the bodyweight, improve plasma lipid profile and hepatic injury of high-fat diet-induced obese mice.
出处 《江苏大学学报(医学版)》 CAS 2016年第2期119-123,共5页 Journal of Jiangsu University:Medicine Edition
基金 镇江市新兴产业科技专项基金资助项目(CY2011026)
关键词 利莫那班衍生物 减肥 脂质代谢 analogues of rimonabant lose weight lipid metabolism
  • 相关文献

参考文献14

  • 1Matias I,Petrosino S,Racioppi A,et al.Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity:effect of high fat diets[J].Mol Cell Endocrinol,2008,286(1/2 Suppl 1):S66-S78.
  • 2Adan RA.Mechanisms underlying current and future anti-obesity drugs[J].Trends Neurosci,2013,36(2):133-140.
  • 3Filippatos TD,Derdemezis CS,Gazi IF,et al.Orlistatassociated adverse effects and drug interactions[J].Drug Saf,2008,31(1):53-65.
  • 4George M,Rajaram M,Shanmugam E.New and emerging drug molecules against obesity[J].J Cardiovasc Pharmacol Ther,2014,19(1):65-76.
  • 5Thomas BF,Francisco ME,Seltzman HH,et al.Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide(SR141716)with unique binding selectivities and pharmacological activities[J].Bioorg Med Chem,2005,13(18):5463-5474.
  • 6Leite CE,Mocelin CA,Petersen GO,et al.Rimonabant:an antagonist drug of the endocannabinoid system for the treatment of obesity[J].Pharmacol Rep,2009,61(2):217-224.
  • 7Gary-Bobo M,Elachouri G,Gallas JF,et al.Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats[J].Hepatology,2007,46(1):122-129.
  • 8Van Gaal LF,Rissanen AM,Scheen AJ,et al.Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe Study[J].Lancet,2005,365(9468):1389-1397.
  • 9Despres JP,Golay A,Sjostrom L.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia[J].N Engl J Med,2005,353(20):2121-2134.
  • 10Jones D.End of the line for cannabinoid receptor 1 as an anti-obesity target[J].Nat Rev Drug Discov,2008,7(12):961-962.

二级参考文献8

  • 1李洁,王玉侠.肥胖发生机制及减肥方法的研究现状[J].中国体育科技,2006,42(2):64-67. 被引量:34
  • 2Laura RA,Alberto RO,Alejandra C,et al.Overweightand obesity:prevalence and their association with somesocial characteristics in a random sample population-basedstudy in C rdoba city,Argentina[J].Obes Res ClinPract,2009,3(2):75-83.
  • 3Yach D,Stuckler D,Brownell KD.Epidemiologic and e-conomic consequences of the global epidemics of obesityand diabetes[J].Nat Med,2006,12(1):62-66.
  • 4Andersson C,Weeke P,Fosb l EL,et al.Acute effect ofweight loss on levels of total bilirubin in obese,cardiovas-cular high-risk patients:an analysis from the lead-in peri-od of the Sibutramine Cardiovascular Outcome trial[J].Metabolism,2009,58(8):1109-1115.
  • 5Filippatos TD,Tsimihodimos V,Kostapanos M,et al.A-nalysis of 6-month effect of orlistat administration,aloneor incombination with fenofibrate,on triglyceride-rich lip-oprotein metabolism in overweight and obese patients withmetabolic syndrome[J].J Clin Lipidol,2008,2(4):279-284.
  • 6Rasmussen EB,Reilly W,Buckley J,et al.Rimonabantreduces the essential value of food in the genetically obeseZucker rat:an exponential demand analysis[J].PhysiolBehav,2012,105(3):734-741.
  • 7Gadde KM,Allison DB.Cannabinoid-1receptor antago-nist,rimonabant,for management of obesity and relatedrisks[J].Circulation,2006,114(9):974-984.
  • 8雷林,周海滨,熊静帆,彭绩,刘小立.深圳市成年居民超重与肥胖流行病学特征的调查[J].公共卫生与预防医学,2011,22(1):35-37. 被引量:28

共引文献1

同被引文献22

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部